China Bozza Development Holdings Limited ( ($HK:1069) ) has issued an update.
China Health Technology Group Holding Company Limited has announced the resignation of executive director Ms. Cao Xiying, effective 15 May 2026, citing other business commitments and noting no disagreement with the board or issues requiring shareholder attention. The board expressed gratitude for her past contributions, signalling a planned and orderly leadership transition rather than a dispute-driven departure.
To fill the vacancy, the company has appointed Ms. Wong Hoi Ying as an executive director from the same date, bringing more than 16 years of experience in auditing, accounting, financial management and regulatory compliance. Wong, a qualified accountant and former independent non-executive director of the company, will serve an initial one-year term on HK$96,000 annual remuneration, a move that underscores the group’s emphasis on financial expertise and continuity in corporate governance.
More about China Bozza Development Holdings Limited
China Health Technology Group Holding Company Limited operates in the health technology sector, focusing on products and services that integrate healthcare with technology-driven solutions. The group is listed in Hong Kong and oversees various subsidiaries, positioning itself within a regulated market that emphasizes governance, transparency and board oversight.
Average Trading Volume: 563,358
Technical Sentiment Signal: Sell
Current Market Cap: HK$97.26M
Learn more about 1069 stock on TipRanks’ Stock Analysis page.
